Vivos Therapeutics audit reports for FY2025 and FY2024 include substantial doubt about going concern

VVOS•2026-10-01

Vivos Therapeutics said audit reports for fiscal 2025 and 2024 include substantial doubt about its ability to continue as a going concern. The company also dismissed Baker Tilly US as its independent auditor, effective September 29, 2026.

1. Audit and auditor change

Vivos Therapeutics said audit reports for fiscal 2025 and 2024 include substantial doubt about its ability to continue as a going concern. The company dismissed Baker Tilly US as its independent auditor, effective September 29, 2026.

Vivos Therapeutics audit reports for FY2025 and FY2024 include substantial doubt about going concern

1. Audit and auditor change

Related News

Cardinal Health enters binding letter of intent to extend distribution agreements with CVS Health

Ovintiv renews share buyback program, targets up to 26,973,037 shares

VisionWave, Sadot form 50/50 joint venture for Composite Materials deal rights

Pursuit submits proposal to develop sightseeing tram near Glacier National Park

TransUnion sets third-quarter results release, earnings call